modelTinzaparin
Extends from Pharmacolibrary.Drugs.ATC.B.B01AB10.
Information
| name: | Tinzaparin | |
| ATC code: | B01AB10 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 4500 | mg |
| volume of distribution: | 3.4 | L |
| clearance: | 1.04 | L/h |
| other parameters in model implementation | ||
Tinzaparin is a low molecular weight heparin (LMWH) used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. It is administered parenterally and is approved for clinical use.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers, both sexes, after subcutaneous administration.
References
Gouin-Thibault, I, et al., & Delavenne, X (2024). Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study. Journal of thrombosis and haemostasis : JTH 22(10) 2864–2872. DOI:10.1016/j.jtha.2024.07.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39019439
Barrett, JS, et al., & Gastonguay, M (2001). Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. International journal of clinical pharmacology and therapeutics 39(10) 431–446. PUBMED:https://pubmed.ncbi.nlm.nih.gov/11680668
Hainer, JW, et al., & Hua, TA (2002). Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation 40(3) 531–538. DOI:10.1053/ajkd.2002.34911 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12200805
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)